Related references
Note: Only part of the references are listed.Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy
Ajlan Al Zaki et al.
BLOOD ADVANCES (2022)
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
Elise A. Chong et al.
BLOOD (2022)
Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 US Academic Institutions
Ajay Major et al.
BLOOD (2022)
End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
Caron A. Jacobson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Mechanisms of resistance to CAR T cell therapy
Nirali N. Shah et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
T cell senescence and CAR-T cell exhaustion in hematological malignancies
Dimitri Kasakovski et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Alexandre V. Hirayama et al.
BLOOD (2018)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Outcomes of hematopoietic cell transplantation using donors or recipients with inherited chromosomally integrated HHV-6
Joshua A. Hill et al.
BLOOD (2017)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Share Paper
